Lin Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lin Guo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Ce Gao
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
6 shared publications- Yun Wang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
6 shared publications Zhidong Liu
Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
5 shared publicationsTianyu Gao
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu Province, China
4 shared publicationsXiaoxia Jia
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Xuzhou China
4 shared publicationsYun Wang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
4 shared publications
Latest Publications
- 21 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 120
Fluvoxamine Attenuates Blood–Brain Barrier Disruption in Drug-Resistance Epilepsy and inhibits Ferroptosis via the Sigma-1 Receptor-TAMM41 signaling in bEnd.3 cells
Drug resistance is common in epileptic patients, necessitating the exploration of novel therapeutic strategies to convert drug resistance into drug responsiveness. The repurposing of existing drugs has emerged as an attractive approach for finding novel drugs. In this study, we utilized a combination of network computation and text mining techniques to identify potential repurposable drugs for treating drug-resistant epilepsy (DRE) and elucidate the underlying mechanisms. Our analysis identified fluvoxamine as a promising candidate for repurposing in epilepsy treatment. Using the lamotrigine-pentylenetetrazol kindling drug-resistant epilepsy model, we found that fluvoxamine effectively converted drug-resistant epilepsy in mice to drug responsiveness, including against gabapentin, phenytoin sodium, and carbamazepine. Additionally, fluvoxamine mitigated the elevated blood–brain barrier permeability associated with drug-resistant epilepsy by activating the sigma-1 receptor (S1R). Furthermore, fluvoxamine inhibited ferroptosis in endothelial cells induced by kainic acid. Proteome test revealed that fluvoxamine increased the expression of TAM41 Mitochondrial Translocator Assembly And Maintenance Homolog (TAMM41), a protein located in the inner mitochondrial membrane of endothelial cells. Notably, the knockdown or conditional knockout of TAMM41 in brain microvascular endothelial cells (BMVECs) reversed the protective effects of fluvoxamine on the blood–brain barrier (BBB) integrity and its inhibitory action on ferroptosis. In contrast, fluoxetine, despite sharing similar pharmacokinetic features and receptor spectrum with fluvoxamine, didn’t elevate TAMM41 levels or exhibit anti-drug-resistant epileptic activity. Collectively, our findings demonstrate that fluvoxamine restores the responsiveness of DRE mice to antiepileptic drugs, alleviates BBB impairment, and inhibits BMVECs ferroptosis by activating the S1R-TAMM41 axis in BMVECs. Given the critical role of BBB disruption in drug-resistant epilepsy pathogenesis, this study may offer novel therapeutic strategies for treating drug-resistant epilepsy.
- 21 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 120
Fluvoxamine Attenuates Blood–Brain Barrier Disruption in Drug-Resistance Epilepsy and inhibits Ferroptosis via the Sigma-1 Receptor-TAMM41 signaling in bEnd.3 cells
Drug resistance is common in epileptic patients, necessitating the exploration of novel therapeutic strategies to convert drug resistance into drug responsiveness. The repurposing of existing drugs has emerged as an attractive approach for finding novel drugs. In this study, we utilized a combination of network computation and text mining techniques to identify potential repurposable drugs for treating drug-resistant epilepsy (DRE) and elucidate the underlying mechanisms. Our analysis identified fluvoxamine as a promising candidate for repurposing in epilepsy treatment. Using the lamotrigine-pentylenetetrazol kindling drug-resistant epilepsy model, we found that fluvoxamine effectively converted drug-resistant epilepsy in mice to drug responsiveness, including against gabapentin, phenytoin sodium, and carbamazepine. Additionally, fluvoxamine mitigated the elevated blood–brain barrier permeability associated with drug-resistant epilepsy by activating the sigma-1 receptor (S1R). Furthermore, fluvoxamine inhibited ferroptosis in endothelial cells induced by kainic acid. Proteome test revealed that fluvoxamine increased the expression of TAM41 Mitochondrial Translocator Assembly And Maintenance Homolog (TAMM41), a protein located in the inner mitochondrial membrane of endothelial cells. Notably, the knockdown or conditional knockout of TAMM41 in brain microvascular endothelial cells (BMVECs) reversed the protective effects of fluvoxamine on the blood–brain barrier (BBB) integrity and its inhibitory action on ferroptosis. In contrast, fluoxetine, despite sharing similar pharmacokinetic features and receptor spectrum with fluvoxamine, didn’t elevate TAMM41 levels or exhibit anti-drug-resistant epileptic activity. Collectively, our findings demonstrate that fluvoxamine restores the responsiveness of DRE mice to antiepileptic drugs, alleviates BBB impairment, and inhibits BMVECs ferroptosis by activating the S1R-TAMM41 axis in BMVECs. Given the critical role of BBB disruption in drug-resistant epilepsy pathogenesis, this study may offer novel therapeutic strategies for treating drug-resistant epilepsy.
- 16 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 243-255
Sustained antidepressant actions of ketamine involve TAMM41-mediated transfer of astrocytic sigma-1 receptor to neuron
Several limitations such as delayed onset and insufficient efficacy exist in current antidepressant treatments, thereby driving the search for new therapeutic approaches. Ketamine produces a rapid and sustained antidepressant response, yet its molecular mechanisms remain elusive. Here, we elucidated that the transfer of sigma-1 receptor (S1R) from astrocytes to neurons was associated with ketamine’s antidepressant effect. Mechanistically, we identified that ketamine activated the mitochondrial protein TAMM41 and then facilitated the transfer of astrocytic S1R via the TAMM41-cardiolipin-exosomes axis. Furthermore, conditional deletion of astrocytic TAMM41 exhibited depressive-like behaviors and abolished the sustained antidepressant effect of ketamine. Inspired by these findings of endogenous exosomes delivering S1R, we devised a strategy to engineer exosome-encapsulated S1R (S1R-EXOs) using exosomes released by human red blood cells and synthetic S1R mRNA. We found that exogenous S1R-EXOs effectively delivered S1R to neurons in S1R knockout mice. Finally, we verified that exogenous S1R-EXOs produced antidepressant-like effect. Our findings reveal that astrocytic TAMM41 underlies the sustained antidepressant effect of ketamine through exosomal delivery of S1R to neurons, offering potential for new strategies in depression treatment. Considering the advantages of human red blood cells and therapeutic mRNA, our results also provide a promising avenue that warrants further translational and clinical exploration.
- 16 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 243-255
Sustained antidepressant actions of ketamine involve TAMM41-mediated transfer of astrocytic sigma-1 receptor to neuron
Several limitations such as delayed onset and insufficient efficacy exist in current antidepressant treatments, thereby driving the search for new therapeutic approaches. Ketamine produces a rapid and sustained antidepressant response, yet its molecular mechanisms remain elusive. Here, we elucidated that the transfer of sigma-1 receptor (S1R) from astrocytes to neurons was associated with ketamine’s antidepressant effect. Mechanistically, we identified that ketamine activated the mitochondrial protein TAMM41 and then facilitated the transfer of astrocytic S1R via the TAMM41-cardiolipin-exosomes axis. Furthermore, conditional deletion of astrocytic TAMM41 exhibited depressive-like behaviors and abolished the sustained antidepressant effect of ketamine. Inspired by these findings of endogenous exosomes delivering S1R, we devised a strategy to engineer exosome-encapsulated S1R (S1R-EXOs) using exosomes released by human red blood cells and synthetic S1R mRNA. We found that exogenous S1R-EXOs effectively delivered S1R to neurons in S1R knockout mice. Finally, we verified that exogenous S1R-EXOs produced antidepressant-like effect. Our findings reveal that astrocytic TAMM41 underlies the sustained antidepressant effect of ketamine through exosomal delivery of S1R to neurons, offering potential for new strategies in depression treatment. Considering the advantages of human red blood cells and therapeutic mRNA, our results also provide a promising avenue that warrants further translational and clinical exploration.
- 17 February 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (6) , 1592-1609
Circular RNA hsa_circ_0000288 protects against epilepsy in mice by binding to and stabilizing caprin1 protein
Current anti-epileptic drugs remain to be unsatisfactory, new therapeutic approaches are needed. Circular RNA is a promising class of therapeutic RNAs. Recent studies have shown the role of circRNA in the pathologic process of epilepsy. In this study, we identified the circRNA in epileptic patients in remission that inhibited the epileptic course. By comparing the profiles of differentially expressed circRNAs in peripheral serum between patients in remission and those not in remission, we found that the level of hsa_circ_0000288 (circ288) was markedly elevated in the epileptic patients in remission. We established a kainic acid-induced status epilepticus model in mice. Overexpression of Circ288 by injecting adeno-associated virus (AAV)-circ288-overexpression vector into hippocampi significantly ameliorated epilepsy-induced neuronal injury, promoted hippocampus neurogenesis, and inhibited abnormal migration of newborn neurons into the dentate hilus. Moreover, circ288 overexpression significantly decreased the epileptiform discharges and the spontaneous seizures in the chronic phase of epileptogenesis and alleviated mood disorders (anxiety, depression), and cognitive deficits in epileptic mice. We revealed that circ288 directly bound to an RNA-binding protein caprin1 and inhibited its degradation. The protective action of circ288 was reversed by the knockdown of caprin1 in an in vitro epileptic model and lost in the neuron-specific caprin1 knockout mice (CaMK2α-Cre:Caprin1f/f). Overexpression of circ288 or caprin1 raised the mRNA level of NMDA receptor 3B, a negative modulator of NMDA receptors, suggesting the involvement of the carpin1-NMDA receptor 3B pathway in the role of circ288. Given the disadvantages of circ288 overexpression by a virus, we constructed exosomes-encapsulated circ288 (EXO-circ288) and demonstrated that tail vein injection of EXO-circ288 exerted robust protective effects. This study provides a new avenue for developing anti-epileptic therapeutic RNAs.
- 17 February 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (6) , 1592-1609
Circular RNA hsa_circ_0000288 protects against epilepsy in mice by binding to and stabilizing caprin1 protein
Current anti-epileptic drugs remain to be unsatisfactory, new therapeutic approaches are needed. Circular RNA is a promising class of therapeutic RNAs. Recent studies have shown the role of circRNA in the pathologic process of epilepsy. In this study, we identified the circRNA in epileptic patients in remission that inhibited the epileptic course. By comparing the profiles of differentially expressed circRNAs in peripheral serum between patients in remission and those not in remission, we found that the level of hsa_circ_0000288 (circ288) was markedly elevated in the epileptic patients in remission. We established a kainic acid-induced status epilepticus model in mice. Overexpression of Circ288 by injecting adeno-associated virus (AAV)-circ288-overexpression vector into hippocampi significantly ameliorated epilepsy-induced neuronal injury, promoted hippocampus neurogenesis, and inhibited abnormal migration of newborn neurons into the dentate hilus. Moreover, circ288 overexpression significantly decreased the epileptiform discharges and the spontaneous seizures in the chronic phase of epileptogenesis and alleviated mood disorders (anxiety, depression), and cognitive deficits in epileptic mice. We revealed that circ288 directly bound to an RNA-binding protein caprin1 and inhibited its degradation. The protective action of circ288 was reversed by the knockdown of caprin1 in an in vitro epileptic model and lost in the neuron-specific caprin1 knockout mice (CaMK2α-Cre:Caprin1f/f). Overexpression of circ288 or caprin1 raised the mRNA level of NMDA receptor 3B, a negative modulator of NMDA receptors, suggesting the involvement of the carpin1-NMDA receptor 3B pathway in the role of circ288. Given the disadvantages of circ288 overexpression by a virus, we constructed exosomes-encapsulated circ288 (EXO-circ288) and demonstrated that tail vein injection of EXO-circ288 exerted robust protective effects. This study provides a new avenue for developing anti-epileptic therapeutic RNAs.
- Open Access
- 10 August 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (2) , 197-208
The sigma‐1 receptor‐TAMM41 axis modulates neuroinflammation and attenuates memory impairment during the latent period of epileptogenesis
Background: Therapy in the latent period is favorable for retarding the process of epileptogenesis. Recently, we have discovered that the activated sigma‐1 receptor (Sig‐1R) attenuates the hippocampus pathological injury and memory impairment in the latent period of epileptogenesis. But the molecular mechanism needs further investigation.Methods: PRE‐084 was utilized as a research tool to highly selectively activate Sig‐1R in epileptic mice. After the treatment of PRE‐084, the pro‐inflammatory cytokines, neuropathological traits, and the level of mitochondrial translocator assembly and maintenance 41 homolog (TAMM41) in the hippocampus were examined. The mode in which the Sig‐1R interacts with TAMM41 was explored. The role of TAMM41 in the protecting effect of PRE‐084 was established.Results: PRE‐084 inhibited the growth of pro‐inflammatory cytokines, reduced the formation of gliosis, alleviated neuronal damage in the hippocampus, and attenuated memory impairment in the latent period of epileptogenesis. The protein level of TAMM41 decreased in the hippocampi of epileptic mice and increased in the PRE‐084‐treated mice. The Sig‐1R bound with TAMM41 directly, maintaining the stability of TAMM41. Knockdown of TAMM41 reversed the protective effect of PRE‐084, and overexpression of TAMM41 exhibited a similar protective action to that of PRE‐084.Conclusion: We presented the concept of the “sigma‐1 receptor–TAMM41 axis” and proposed that augmenting this axis can attenuate neuroinflammation and memory impairment in the process of epileptogenesis.
- 10 August 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (2) , 197-208
Open AccessThe sigma‐1 receptor‐TAMM41 axis modulates neuroinflammation and attenuates memory impairment during the latent period of epileptogenesis
Background: Therapy in the latent period is favorable for retarding the process of epileptogenesis. Recently, we have discovered that the activated sigma‐1 receptor (Sig‐1R) attenuates the hippocampus pathological injury and memory impairment in the latent period of epileptogenesis. But the molecular mechanism needs further investigation.Methods: PRE‐084 was utilized as a research tool to highly selectively activate Sig‐1R in epileptic mice. After the treatment of PRE‐084, the pro‐inflammatory cytokines, neuropathological traits, and the level of mitochondrial translocator assembly and maintenance 41 homolog (TAMM41) in the hippocampus were examined. The mode in which the Sig‐1R interacts with TAMM41 was explored. The role of TAMM41 in the protecting effect of PRE‐084 was established.Results: PRE‐084 inhibited the growth of pro‐inflammatory cytokines, reduced the formation of gliosis, alleviated neuronal damage in the hippocampus, and attenuated memory impairment in the latent period of epileptogenesis. The protein level of TAMM41 decreased in the hippocampi of epileptic mice and increased in the PRE‐084‐treated mice. The Sig‐1R bound with TAMM41 directly, maintaining the stability of TAMM41. Knockdown of TAMM41 reversed the protective effect of PRE‐084, and overexpression of TAMM41 exhibited a similar protective action to that of PRE‐084.Conclusion: We presented the concept of the “sigma‐1 receptor–TAMM41 axis” and proposed that augmenting this axis can attenuate neuroinflammation and memory impairment in the process of epileptogenesis.
- 4 November 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (22) , 3198-3209
SKF83959 Attenuates Memory Impairment and Depressive-like Behavior during the Latent Period of Epilepsy via Allosteric Activation of the Sigma-1 Receptor
Memory impairment and emotional disorder are two common clinical comorbidities in patients with epilepsy. It is imperative to develop a novel therapeutic agent or a strategy. 6 Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) is a dopamine-1 receptor agonist and sigma-1 receptor allosteric modulator, which displays the neuron-protective and anti-neuroinflammation activity. We examined the effect of SKF83959 on the memory impairment and emotional disorder in the latent period of epilepsy using the mice post-status epilepticus model. We found that SKF83959 ameliorated memory impairment and depressive-like mood, alleviated the neuron damage and the formation of gliosis in hippocampus, suppressed the rise of pro-inflammatory cytokines, including tumor necrosis factor -a and interleukin-1fi, and induced nitric oxide synthase in the latent period of epilepsy. Additionally, SKF83959 significantly inhibited the activity of calcineurin and glycogen synthase kinase-3fi. All of these protective actions were reversed by BD1047 (a sigma-1 receptor antagonist). In addition, the intra-hippocampus injection of ketoconazole (a dehydroepiandrosterone synthesis inhibitor) also reversed the protective activity of SKF83959. Thus, we concluded that SKF83959 ameliorated the memory impairment and depressive-like mood in epilepsy via allosterically activating the sigma-1 receptor and subsequently inhibiting the calcineurin/glycogen synthase kinase-3fi pathway.
- 4 November 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (22) , 3198-3209
SKF83959 Attenuates Memory Impairment and Depressive-like Behavior during the Latent Period of Epilepsy via Allosteric Activation of the Sigma-1 Receptor
Memory impairment and emotional disorder are two common clinical comorbidities in patients with epilepsy. It is imperative to develop a novel therapeutic agent or a strategy. 6 Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) is a dopamine-1 receptor agonist and sigma-1 receptor allosteric modulator, which displays the neuron-protective and anti-neuroinflammation activity. We examined the effect of SKF83959 on the memory impairment and emotional disorder in the latent period of epilepsy using the mice post-status epilepticus model. We found that SKF83959 ameliorated memory impairment and depressive-like mood, alleviated the neuron damage and the formation of gliosis in hippocampus, suppressed the rise of pro-inflammatory cytokines, including tumor necrosis factor -a and interleukin-1fi, and induced nitric oxide synthase in the latent period of epilepsy. Additionally, SKF83959 significantly inhibited the activity of calcineurin and glycogen synthase kinase-3fi. All of these protective actions were reversed by BD1047 (a sigma-1 receptor antagonist). In addition, the intra-hippocampus injection of ketoconazole (a dehydroepiandrosterone synthesis inhibitor) also reversed the protective activity of SKF83959. Thus, we concluded that SKF83959 ameliorated the memory impairment and depressive-like mood in epilepsy via allosterically activating the sigma-1 receptor and subsequently inhibiting the calcineurin/glycogen synthase kinase-3fi pathway.
- 10 November 2021
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 395 (1) , 119-120
Correction to: Pharmacological stimulation of sigma-1 receptor promotes activation of astrocyte via ERK1/2 and GSK3β signaling pathway
- 10 November 2021
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 395 (1) , 119-120
Correction to: Pharmacological stimulation of sigma-1 receptor promotes activation of astrocyte via ERK1/2 and GSK3β signaling pathway
- 1 September 2021
- Published by Springer Nature in Neurochemical Research
- Vol. 47 (2) , 264-278
Inhibition of Noncanonical Ca2+ Oscillation/Calcineurin/GSK-3β Pathway Contributes to Anti-Inflammatory Effect of Sigma-1 Receptor Activation
Further understanding the mechanism for microglia activation is necessary for developing novel anti-inflammatory strategies. Our previous study found that the activation of sigma-1 receptor can effectively inhibit the neuroinflammation, independent of the canonical mechanisms, such as NF-κB, JNK and ERK inflammatory pathways. Thus, it is reasonable that an un-identified, non-canonical pathway contributes to the activation of microglia. In the present study, we found that a sigma-1 receptor agonist of 2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate (PRE-084) suppressed lipopolysaccharide (LPS) elevated nitric oxide (NO) content in BV-2 microglia culture supernatant and LPS-raised mRNA levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS) in BV-2 microglia. Moreover, PRE-084 alleviated LPS-increased Ser 9 de-phosphorylation of glycogen synthase kinase-3 beta (GSK-3β), LPS-elevated catalytic activity of calcineurin, and LPS-raised percent and frequency of Ca2+ oscillatory BV-2 cells. We further found that the inhibitory effect of PRE-084 was reversed by a calcineurin activator of chlorogenic acid and a GSK-3β activator of pyrvinium. Moreover, an IP3 receptor inhibitor of 2-aminoethoxydiphenyl borate mimicked the anti-inflammatory activity of PRE-084. Thus, we identified a noncanonical pro-neuroinflammary pathway of Ca2+ oscillation/Calcineurin/GSK-3β and the inhibition of this pathway is necessary for the anti-inflammatory activity of sigma-1 receptor activation.
- 1 September 2021
- Published by Springer Nature in Neurochemical Research
- Vol. 47 (2) , 264-278
Inhibition of Noncanonical Ca2+ Oscillation/Calcineurin/GSK-3β Pathway Contributes to Anti-Inflammatory Effect of Sigma-1 Receptor Activation
Further understanding the mechanism for microglia activation is necessary for developing novel anti-inflammatory strategies. Our previous study found that the activation of sigma-1 receptor can effectively inhibit the neuroinflammation, independent of the canonical mechanisms, such as NF-κB, JNK and ERK inflammatory pathways. Thus, it is reasonable that an un-identified, non-canonical pathway contributes to the activation of microglia. In the present study, we found that a sigma-1 receptor agonist of 2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate (PRE-084) suppressed lipopolysaccharide (LPS) elevated nitric oxide (NO) content in BV-2 microglia culture supernatant and LPS-raised mRNA levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS) in BV-2 microglia. Moreover, PRE-084 alleviated LPS-increased Ser 9 de-phosphorylation of glycogen synthase kinase-3 beta (GSK-3β), LPS-elevated catalytic activity of calcineurin, and LPS-raised percent and frequency of Ca2+ oscillatory BV-2 cells. We further found that the inhibitory effect of PRE-084 was reversed by a calcineurin activator of chlorogenic acid and a GSK-3β activator of pyrvinium. Moreover, an IP3 receptor inhibitor of 2-aminoethoxydiphenyl borate mimicked the anti-inflammatory activity of PRE-084. Thus, we identified a noncanonical pro-neuroinflammary pathway of Ca2+ oscillation/Calcineurin/GSK-3β and the inhibition of this pathway is necessary for the anti-inflammatory activity of sigma-1 receptor activation.
- 1 July 2021
- Published by Elsevier in Behavioural Brain Research
- Vol. 410, 113344
Stimulation of astrocytic sigma-1 receptor is sufficient to ameliorate inflammation- induced depression
- 1 July 2021
- Published by Elsevier in Behavioural Brain Research
- Vol. 410, 113344
Stimulation of astrocytic sigma-1 receptor is sufficient to ameliorate inflammation- induced depression
- 1 May 2021
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 94, 225-234
Plasma exosomes from depression ameliorate inflammation-induced depressive-like behaviors via sigma-1 receptor delivery
- 1 May 2021
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 94, 225-234
Plasma exosomes from depression ameliorate inflammation-induced depressive-like behaviors via sigma-1 receptor delivery
- 23 February 2019
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 392 (7) , 801-812
Pharmacological stimulation of sigma-1 receptor promotes activation of astrocyte via ERK1/2 and GSK3β signaling pathway
Astrocyte is considered to be a type of passive supportive cells that preserves neuronal activity and survival. The dysfunction of astrocytes is involved in the pathological processes of major depression. Recent studies implicate sigma-1 receptors as putative therapeutic targets for current available antidepressant drugs. However, it is absent of direct evidences whether sigma-1 receptor could promote activation of astrocyte. In the present study, we took advantage of primary astrocyte culture and a highly selective agonist of sigma-1 receptor, (+)SKF-10047 to determine the effect of sigma-1 receptor on Brdu (bromodeoxyuridine) labeling positive cells, migration as well as GFAP (glial fibrillary acidic protein) expression of astrocyte. The results showed that (+)SKF-10047 notably increased the number of Brdu labeling positive cells, migration, and the expression of GFAP in primary astrocytes, which were blocked by antagonist of sigma-1 receptor. Moreover, we also found that (+)SKF-10047 increased the phosphorylation of ERK1/2 (extracellular signal-regulated kinases 1/2) and GSK3β (glycogen synthase kinase 3β) (ser 9) in the primary astrocytes. In addition, pharmacological inhibition of ERK1/2 and GSK3β (ser 9) abolished sigma-1 receptor-promoted activation of astrocyte. Therefore, sigma-1 receptor could be considerate as a new pattern for modulating astrocytic function might emerge as therapeutic strategies.
- 23 February 2019
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 392 (7) , 801-812
Pharmacological stimulation of sigma-1 receptor promotes activation of astrocyte via ERK1/2 and GSK3β signaling pathway
Astrocyte is considered to be a type of passive supportive cells that preserves neuronal activity and survival. The dysfunction of astrocytes is involved in the pathological processes of major depression. Recent studies implicate sigma-1 receptors as putative therapeutic targets for current available antidepressant drugs. However, it is absent of direct evidences whether sigma-1 receptor could promote activation of astrocyte. In the present study, we took advantage of primary astrocyte culture and a highly selective agonist of sigma-1 receptor, (+)SKF-10047 to determine the effect of sigma-1 receptor on Brdu (bromodeoxyuridine) labeling positive cells, migration as well as GFAP (glial fibrillary acidic protein) expression of astrocyte. The results showed that (+)SKF-10047 notably increased the number of Brdu labeling positive cells, migration, and the expression of GFAP in primary astrocytes, which were blocked by antagonist of sigma-1 receptor. Moreover, we also found that (+)SKF-10047 increased the phosphorylation of ERK1/2 (extracellular signal-regulated kinases 1/2) and GSK3β (glycogen synthase kinase 3β) (ser 9) in the primary astrocytes. In addition, pharmacological inhibition of ERK1/2 and GSK3β (ser 9) abolished sigma-1 receptor-promoted activation of astrocyte. Therefore, sigma-1 receptor could be considerate as a new pattern for modulating astrocytic function might emerge as therapeutic strategies.